Gargi Talukder, Ph.D., serves as the leader of Orrick's Life Sciences Patent Strategy and Prosecution Practice. Companies at all stages of development rely on Gargi’s advice for global patent portfolio management and prosecution and competitive landscape assessments. Gargi works with scientific leads and senior management of leading biotechnology and pharmaceutical companies to develop strategies for patent procurement and product clearance across a range of life sciences technology sectors, such as protein therapeutics, gene therapy, and genomics and proteomics applications.
Gargi’s work in protein therapeutics includes patent estate development for antibody and fusion protein therapeutics and utilizes her knowledge of the patent landscape in this area to inform strategic portfolio management. In the fields of genomics and proteomics, she has conducted diligence and developed portfolios related to the biochemistry of sequencing technologies, as well as to the associated devices and machine learning methods utilized in sequencing methods. In the field of cancer immunotherapies (immuno-oncology), she has developed portfolios related to cell-based immunotherapy approaches, including targeted immune cell therapies and immunological pathway interventions.
In addition, Gargi assists clients in providing intellectual property support for transactional matters, including diligence for mergers and acquisitions as well as financing rounds. Her technical experience is routinely called upon in helping to develop litigation strategies for complex and high-stakes trials.
Gargi has authored scientific papers in peer-reviewed publications, as well as articles discussing medical and biological research in general-interest newspapers and periodicals. Her doctoral work in Neuroscience from Stanford University focused on structure-function studies in ion channels, with an emphasis on using genetic engineering and electrophysiology to identify structural elements of potassium channels that lead to their voltage and chemical sensitivity.
Advised multi-national pharmaceutical and biotechnology companies on matters related to intellectual property and corporate transactions, including development of patent portfolios, assessment of patent landscapes, and analysis of identified portfolios for acquisition diligences.
Worked with emerging biotechnology companies in the genomics and proteomics sectors on strategic global patent estate management to meet scientific goals and identify ways to cover and evolve with product pipeline, with tailored advice based on patent landscape assessments and identification of target features to highlight in future patent procurement efforts.
Advised venture capital and private equity firms on investment targets, with patent estate assessments and freedom to operate clearances structured to meet the level of investments and risks posed by patent landscape.